---

Assessment and comparison of clinico-microbiological efficacy of moxifloxacin plus vancomycin combined therapy with fortified vancomycin in bacterial keratitis

---

Original Article

Author Details : Ahmad Abdullah*, S N Askari, Shamim Ahmad, Yasir Alvi

Volume : 7, Issue : 2, Year : 2021

Article Page : 327-332

https://doi.org/10.18231/j.ijceo.2021.065

Suggest article by email

Get Permission

---

Abstract

Aim: To assess and compare clinico-microbiological efficacy of Moxifloxacin (0.5%) plus Vancomycin (2.5%) combined therapy to Fortified Vancomycin (5%) in bacterial keratitis.
Materials and Methods: The present study was conducted on patients who visited eye OPD, J.N.M.C.H and Gandhi Eye Hospital, Aligarh. Patients with bacterial keratitis were diagnosed and included in the study. Right eyes were instilled moxifloxacin plus vancomycin combination therapy and Left eyes were instilled fortified vancomycin. Microbiological results were recorded on first visit and on follow up visits during course of treatment.
Results: Total of 32 patients were included in the study. At first visit, only 8 cases were positive for bacterial culture with coagulase negative Staphylococcus (CoNS) being the most common organisms. All the smears became negative in first follow-up (7th day) in both the groups. No significant difference were found in clinical and microbiological study outcome betweenthe two-study groups.
Conclusions: We conclude that both the drugs, i.e. moxifloxacin (0.5%) plus vancomycin (2.5%) combined therapy and fortified vancomycin (5%) had good efficiency clinically and in microbial elimination in cases of bacterial keratitis with equivalent outcome.

Keywords: Keratitis, Corneal ulcer, Bacterial keratitis, Efficacy.

How to cite : Abdullah A, Askari S N, Ahmad S, Alvi Y, Assessment and comparison of clinico-microbiological efficacy of moxifloxacin plus vancomycin combined therapy with fortified vancomycin in bacterial keratitis. Indian J Clin Exp Ophthalmol 2021;7(2):327-332

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.